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Abstract
Recent years have witnessed new innovation in Bayesian techniques to adjust for unmeasured
confounding. A challenge with existing methods is that the user is often required to elicit
prior distributions for high dimensional parameters that model competing bias scenarios. This
can render the methods unwieldy. In this paper we propose a novel methodology to adjust
for unmeasured confounding that derives default priors for bias parameters for observational
studies with binary covariates. The confounding effects of measured and unmeasured variables
are treated as exchangeable within a Bayesian framework. We model the joint distribution of
covariates using a loglinear model with pairwise interaction terms. Hierarchical priors constrain
the magnitude and direction of bias parameters. An appealing property of the method is that
the conditional distribution of the unmeasured confounder follows a logistic model, giving a
simple equivalence with previously proposed methods. We apply the method in a data example
from pharmacoepidemiology and explore the impact of different priors for bias parameters on
the analysis results.
Keywords: bias; observational studies; Bayesian statistics, pharmacoepidemiology
Running title: Bayesian Sensitivity Analysis
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1. Introduction
1.1 Unmeasured Confounding in Pharmacoepidemiology
Bias from unmeasured confounding figures prominently in pharmacoepidemiology, which is
concerned with improving our understanding of the effectiveness and safety of medications.
A typical pharmacoepidemiology study compares outcome response rates in patients who were
prescribed a medication with those that were not. Study findings are often biased without careful
adjustment for the factors that influence prescribing. Unfortunately, control of confounding
is notoriously difficult because medication prescribing is intimately connected to the disease
process that determines the study outcome. The myriad of patient characteristics that influence
prescribing can act as powerful confounders and bias effect estimates in a manner that is difficult
to predict. Epidemiologists call this confounding by indication because the confounders are the
clinical indications for treatment [1].
In this paper, we illustrate the problem of unmeasured confounding using the data example
of McCandless, Gustafson and Levy [2,3]. The authors conducted a retrospective cohort study
to estimate the effect of beta blocker therapy on mortality in heart failure patients living in
British Columbia. We have healthcare administrative data for 6969 persons discharged from
hospital in 1999 and 2000 after treatment for heart failure. We followed them for one year
and 1755 died. Interest lies on the association between beta blocker therapy and mortality,
but the data only provide basic information on the many possible confounders. A total of 21
covariates are available in the data, including patient characteristics, disease indicator variables
and prescribing of cardiovascular therapies. See Table 1 for a complete listing.
Let X and Y denote binary variables modeling the treatment and outcome variables respec-
tively. We set X equal one if the patient was dispensed a beta blocker within thirty days of
hospital discharge, and zero otherwise. Similarly, we let Y denote an indicator variable for death
within one year of hospital discharge. We let C = (C1, . . . , Cp) denote the p = 21 dimensional
vector of covariates listed in Table 1. In pharmacoepidemiological studies of cardiovascular ther-
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apies, interest centers on confounding induced by the various patient illnesses. The vector C
includes q = 9 disease indicator variables measured at baseline including cerebrovascular disease
(CVD), chronic obstructive pulmonary disorder (COPD), hyponatremia (HYPNAT), metastatic
disorder (MTSTD), renal disease (MSRD), ventricular arrhythmia (VENTRAR), liver disease
(MLD), cancer (CAN), and cardiogenic shock (CARS).
To estimate the association between beta blocker therapy and mortality while adjusting
for confounding, we fit a logistic regression of Y on X and C . The results are presented in
the first column of Table 1 under the heading “Naive Analysis”. The table displays regression
coefficients, which are log odds ratios, with 95% interval estimates. The regression coefficient for
the treatment effect X is estimated as -0.32 with 95% interval estimates (-0.48, -0.16), suggesting
that beta blocker therapy reduces mortality. The corresponding odds ratio exp(−0.32) = 0.72
agrees closely with estimates reported from randomized trials of beta blockers and heart failure.
In a scientific review of meta-analyses of randomized trials, Foody, Farrell and Krumholz [4],
found that beta blocker use is associated with a consistent 30% reduction in mortality compared
to placebo.
Nonetheless, there are concerns about unmeasured confounding. The problem is that the
probability of being prescribed a beta blocker is influenced by severity of heart disease in the
patient, which in turn affects risk of death. This analysis uses healthcare administrative data
and it is unclear whether or not we can adequately measure and adjust for severity of heart dis-
ease. The data contain no detailed clinical information on the factors that influence prescribing,
which are recorded on medical charts. For example, one unmeasured confounder is the class
of heart failure. This is an ordinal variable with four categories that indicates the severity of
heart failure. Another unmeasured confounder is ejection fraction, which is a measure of heart
function. Both of these variables are important predictors of mortality and treatment (Foody
et al., 2002). They can either increase or decrease the probability of receiving a beta blocker,
depending on the preferences of the prescribing physician. See Glynn et al. [5] for review of
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how cardiovascular therapies are prescribed in North America.
1.2 Bayesian Sensitivity Analysis for Unmeasured Confounding and the Chal-
lenges of Prior Elicitation for Bias Parameters
A typical sensitivity analysis for unmeasured confounding posits the existence of a unmea-
sured binary variable U which confounds the association between X and Y . Paralleling exist-
ing modelling frameworks (e.g. [2,3,6-9]), we model the probability density P (Y, U |X, C ) =
P (Y |X, C , U)P (U |X, C ) where
logit[P (Y = 1|X, C , U)] = β0 + βXYX + βCY T C + βUYU (1)
logit[P (U = 1|X, C )] = γU + γXUX + γCU T C . (2)
See Table 2 for a detailed explanation of the variables and parameters. Equation (1) includes U
as a missing covariate in the regression model for the outcome. Equation (2) characterizes the
distribution of the missing confounder. The quantity βXY is the parameter of primary interest
and is the causal log odds ratio for the effect of X on Y conditional on (C , U). Provided that
all models are correctly specified and there are no additional unmeasured confounders, then
the parameter βXY has a causal interpretation. The quantities βUY , γU , γXU and γCU are bias
parameters because they determine the magnitude of unmeasured confounding. The parameter
βUY governs the association between U and Y , conditional on (X, C ), while the parameters γXU
and γ CU captures the associations between U and (X, C ). The quantity exp(γU)/(1+exp(γU))
is the prevalence of U = 1 when X = 0 and C1, . . . , C21 = 0. See Table 2 for details.
The variable U is completely unmeasured. Consequently, the data provide no information
about the relationship between U and the measured variables Y , X and C , and the model
is nonidentifiable. But nonidentifiability does not preclude Bayesian model fitting if additional
sources of information are incorporated. Recent years have witnessed the development of numer-
ous techniques for Bayesian adjustment for unmeasured or partially measured confounders. See
for example [2,3,9-11]. A Bayesian strategy would start by assigning proper prior distributions
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to model parameters that translate beliefs about the magnitude and direction of confounding
by U . Bayes Theorem provides a mechanism for model fitting which synthesizes the data with
prior information about bias. We study the posterior distribution for the treatment effect βXY
integrating over the unmeasured confounder U . Posterior credible intervals for the treatment
effect account for uncertainty in the amount of bias from unmeasured confounding in addition
to random error.
A difficulty with Bayesian sensitivity analysis is eliciting prior distributions for the bias
parameters. In particular, the quantities γU , γXU , γCU consist of p + 2 different parameters
that characterize how U is distributed within levels of X and C . In many applications, it is
burdensome to obtain reasonable prior guesses for γ CU , which describes the association between
C and U given X. An additional problem with using equations (1) and (2) for sensitivity
analysis is that there are many combinations of bias parameters that are equally plausible. This
can make it difficult to display results without presenting many tables.
To mitigate this problem, virtually all sensitivity analysis techniques assume that the un-
measured confounder is independent of measured confounders, conditional on treatment. Math-
ematically, we write U ⊥⊥ C |X, where “⊥⊥” denotes conditional independence. See [1-3,6,8,9]
for examples and [1,12-14] for discussion. In equations (1) and (2), this assumption forces
γCU = 0 , where 0 is a zero vector of length p + 1, and then explores sensitivity for the
remaining bias parameters βUY , γXU and γU .
VanderWeele [12] and Herna´n and Robins [13] argue that it is unrealistic to assume that
U ⊥⊥ C |X . Furthermore, epidemiologists argue that such assumptions give inferences from
sensitivity analysis that are too pessimistic [1,14]. In a simulation study, Fewell et al. [14]
demonstrate that high correlations between measured and unmeasured confounders tends to
reduce bias from unmeasured confounding. Intuitively, the reason is because adjusting for mea-
sured variables may control for unmeasured variables because they are correlated with one
another. This reasoning suggests that forcing γCU = 0 for convenience may actually exaggerate
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the sensitivity of the analysis results to unmeasured confounding.
1.3 Correlations Between Measured and Unmeasured Confounders in the Beta
Blocker Data
Returning to the beta blocker example, we attempt to elicit judgments about plausible values
for the bias parameters βUY , γU , γXU and γCU . Table 3 describes the confounding induced
by the q = 9 disease indicator variables listed in Table 1. In Section A we list the conditional
log odds ratios for the association between each variable and mortality by copying and pasting
from the Naive analysis column of Table 1. Section B describe the pairwise conditional asso-
ciations among the variables X and the q = 9 disease indicator variables. In Section B, we
fit a loglinear model by maximum likelihood to the 2 × 2 × . . . × 2 contingency table of cell
counts over all combinations of X and the q = 9 binary disease indicator variables that are
included in C = (C1, . . . , C21). The regression model includes 10 main effects and all
(
10
2
)
= 45
pairwise interactions. Section B contains point estimates and standard errors of coefficients of
the interaction terms in the loglinear model. These coefficients correspond to conditional log
odds ratios for pairwise associations between variables [15]. Elements denoted “NA” indicate
terms that were dropped from the model due to sparsity in order to obtain a valid maximum
likelihood estimator. Section C of Table 3 gives the prevalences of the disease variables.
Table 3 suggests that the disease indicator variables are confounders for the effect of X on
Y , and furthermore, that they are correlated with one another. Most of the variables show
associations with X and Y (Section A). Furthermore, evidence from the literature indicates
that they are predictors of mortality in heart failure patients and they influence prescribing of
cardiovascular therapies [5,16]. Therefore they induce confounding. But the disease variables are
also correlated with one another. In Section B of Table 3, most of the log odds ratios are greater
than zero. Figure 1 plots the log odds ratios. The sample mean is equal to 0.71, which gives
an average odds ratio of exp(0.71)=2.05. This suggests that in the beta blocker data, patients
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who have one disease are also likely to have other diseases. In other words, the confounders are
correlated with one another.
The missing confounder U is a binary indicator of the severity of heart disease, such as
ejection fraction or class of heart failure. Both of these quantities are measures of heart function.
In formulating judgments about U , it is possible that U is correlated with C . Vassan et al.
[17] studied ejection fraction in heart failure patients and showed that patients with low ejection
fraction are more likely to have diabetes, hypertension, high blood pressure and other chronic
illnesses. This suggests that adjustment for C in the Naive analysis of Table 1 may also control
for confounding from U . Therefore, if we do a sensitivity analysis assuming that γC = 0 (i.e.
assuming U ⊥⊥ C |X) then this may exagerate the bias from U .
Thus we are faced with a conundrum: One the one hand it seems unrealistic and possibly
harmful to assume that γC = 0 in sensitivity analysis. But on the other hand it is not clear
how to assign a prior for γC because it is a p-dimensional vector and there is only limited
information available about U .
1.4 Plan of the Paper
One way to elicit priors for the bias parameters is to assume that the confounding effects of
measured and unmeasured confounders are exchangeable in a Bayesian analysis. In other words,
to assume that the confounding induced by U is similar in magnitude to the confounding induced
by C . The assumption of exchangeability is a strong one, however it is has been used previously
in epidemiology to form qualitative judgments about unmeasured confounding. For example, in
a 2002 review paper on confounding by indication, Joffe [18] writes that “... one can learn about
unmeasured confounders and confounding from measured factors. The argument is sometimes
advanced that if adjustment for known covariates fails to change the measure of effect, there
must be little residual confounding.... When control for measured factors reveals confounding,
it is then more likely that there is residual confounding.” This logic rests on the assumption
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that the measured and unmeasured confounders are similar. If the investigator collects enough
covariate information on the patients in the study, then this can be used to characterize the bias
that would be produced from a confounder that was missing. Other examples of this reasoning
from pharmacoepidemiology are described by Schneeweiss [1].
McCandless et al. [3] and Gustafson et al. [19] describe Bayesian methods that assume
exchangeability in the confounding effects of measured and unmeasured confounders. In the
paper of McCandless et al. [3], the authors analyze the beta blocker data, but they ignore
the bias parameter γCU altogether because of the difficulties of prior elicitation. Gustafson
et al. [19] consider the specific case where all of the measured covariates are continuous and
are assumed to have a multivariate Gaussian distribution. Their approach involves estimating
the covariance matrix of the covariates and then using it to construct a prior distribution for
bias parameters. However, the method of Gustafson et al. [19] cannot be used with binary
covariates, as is the case with the beta blocker data.
In this article, we propose a new method for that accommodates observational studies with
binary covariates. We model the joint distribution of (X, C , U) using a loglinear model with
pairwise interactions. Hierarchical priors borrow information from C in order to learn about
bias from U . The method has the appealing property that conditioning on (X, C ) yields a
logistic model for unmeasured confounding that is identical to that of McCandless et al. [2,3]
and Lin et al. [8]. Section 2 describes the method including the model, prior distributions and
posterior computation using Markov chain Monte Carlo (MCMC). The exchangeability assump-
tion is a strong one, and we discuss the plausibility and generality of our method in Section 2.2.
In Section 3, we apply the method to the beta blocker data. A key objective of this article is
to investigate the impact of the prevailing approach to sensitivity analysis which assumes zero
correlation between measured and unmeasured confounders. We study the results when using
degenerate zero mass priors that force γCU = 0. Following the logic of Schneeweiss [1] and
Fewell et al. [14], we illustrate that if U and C are highly correlated, then confounding from U
9
tends to diminish. In the beta blocker data, setting γCU = 0 for convenience gives conclusions
that are too pessimistic. Section 4 concludes with a discussion.
2. Bayesian Adjustment for Unmeasured Confounding
2.1 Model
We model the joint probability density P (Y,X, C , U) = P (Y |X, C , U)P (X, C , U) as
logit[Pr(Y = 1|X, C , U)] = β0 + βXYX + β TCY C + βUY U (3)
P (X, C , U) =
1
Q(γX , γC , γU , γXU , γCU , γCX , γC⊕C )
×
exp
{
γXX + γC T C + γUU+
γXUXU + γCU T C U + γCX T CX + γC⊕C T (C ⊕ C )
}
. (4)
Equation (3) is identical to equation (1) and models the log odds of the outcome as a function of
X, C and U . Equation (4) is a loglinear model for the joint distribution of (X, C , U) with main
effects and pairwise interactions [15]. The denominator Q(γX , γC , γU , γXU , γCU , γCX , γC⊕C )
is the constant of normalization and is a summation of the numerator of equation (4) over the
support of the binary (U,X, C ), which is a set with 2p+2 elements.
See Table 2 for a description of variables and parameters. The quantities γX , γC , γU are
the main effects of (X,U, C ) in the loglinear model, whereas γXU , γCU , γCX and γC⊕C
govern the interaction terms. The quantity C ⊕ C denotes the vector of length (p
2
)
of pairwise
products among the p components of C = (C1, . . . , Cp). In other words,
C ⊕ C = (C1C2, C1C3 , . . . , C1Cp,
C2C3, C2C4, . . . , C2Cp,
Cp−1Cp).
The parameter γC⊕C is a vector of regression coefficients for the interaction terms C ⊕ C ,
and it capture the pairwise conditional associations between components of C .
There is a well-known connection between logistic and loglinear models through conditioning
[15]. The parameters γXU and γCU are conditional log odds ratios for the association between
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(X, C ) and U . If we take P (X, C , U) from equation (4) and condition on (X, C ), then
P (U |X, C ) obeys equation (2). We have
logit[P (U = 1|X, C )] = log
[
P (U = 1|X, C )
P (U = 0|X, C )
]
= log
[
P (U = 1, X, C )
P (U = 0, X, C )
]
= log
[
exp
{
γXX + γC T C + γU+
γXUX + γCU T C + γCX T CX + γC⊕C T (C ⊕ C )
}
/
exp
{
γXX + γC T C + γCX T CX + γC⊕C T (C ⊕ C )
}]
.
= γU + γXUX + γCU T C .
This gives an appealing equivalence between our proposed model and previously proposed mod-
els for unmeasured confounding given by McCandless et al. [2,3], Lin et al. [8]. See also the
model of Rosenbaum and Rubin [6].
2.2 Prior Distributions
Suppose that θ1, θ2, . . . , θJ are a collection of J unknown parameters. In Bayesian analysis, we
say that θ1, θ2, . . . , θJ are exchangeable in their joint distribution if P (θ1, θ2, . . . , θJ) is invariant
to the permutation of the indices (1, . . . , J) [20]. An exchangeable prior distribution is plausible
if, based on the available information, we are unable to distinguish one parameter from another.
Gelman et al. [20] writes that “In practice, ignorance implies exchangeability. Generally, the less
we know about a problem, the more confidently we can make claims about of exchangeability”.
Now suppose that θ1, θ2, . . . , θJ are exchangeable. Then following standard principles of
Bayesian analysis, we can apply de Finetti’s Theorem, which states that in the limit as J →∞,
then under standard regularity conditions any exchangeable distribution for θ1, θ2, . . . , θJ can be
expressed as an independent and identically distributed mixture of random variables conditional
on some latent variable [20]. In other words, θ1, θ2, . . . , θJ can be modelled as a random sample
from a distribution. Technically, the theorem does not apply for finite J . See Bernardo and
Smith [21] for further discussion of exchangeability.
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Building on the discussion of unmeasured confounding in Section 1, we model the confounding
effects of U and C as exchangeable. For the outcome model, we assign a diffuse normal prior
to β0 with mean zero and variance 10
3, and we assign
βXY , βCY , βUY
IID∼ N(0, σ2β) (5)
σ2β ∼ Inv-χ2
(
10−3, 10−3
)
.
The left hand side (LHS) of equation (5) refers to the individual components of βXY , βCY , βUY ,
and Inv-χ2{.} is an inverse χ2 distribution with degrees of freedom 10−3 and scale parameter
10−3. This choice of hyperparameters gives priors that are proper but uninformative. Equation
(5) models the conditional associations between (X, C , U) and Y as exchangeable. The variance
parameter σ2β shares information between C and U . If σ
2
β is small, then this shrinks the posterior
for the bias parameter βUY towards zero to reflect that there is less unmeasured confounding.
Eliciting a prior for γXU and γCU is more challenging because the parameters describe the
manner in which U is distributed within levels of X and C . As described in Section 2.1, a
well-known property of log linear models is the equivalence with logistic regression that arises
through conditioning. The regression coefficients γXU , γCU , γCX , γC⊕C are conditional log
odds ratios for pairwise associations among the components of (X, C , U). Consequently, we
assign
γXU , γCU , γCX , γC⊕C
IID∼ N(µγ, σ2γ) (6)
µγ|σ2γ ∼ N(0, σ2γ)
σ2γ ∼ Inv-χ2
(
10−3, 10−3
)
,
where the LHS of equation (6) refers to the individual components of γXU , γCU , γCX , γC⊕C .
Equation (6) models the pairwise conditional associations among (X, C , U) as exchangeable.
The parameter µγ is the mean log odds ratio and σ
2
γ is the variance.
Finally, we assign priors to the remaining model parameters γX , γC and γU , which are the
main effects in the loglinear model of equation (4). The quantity exp(γU)/(1 + exp(γU)) is the
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prevalence of U = 1 when X = 0 and C1, . . . , C21 = 0. We model the quantities γX , γC and γU
as exchangeable and assign
γX , γC , γU
IID∼ N(µ0, σ20) (7)
µ0|σ20 ∼ N(0, σ20)
σ20 ∼ Inv-χ2
(
10−3, 10−3
)
.
2.3 Model Fitting and Computation
Denote the data as data = {(Yi, Xi, C i); i = 1, . . . , n}. If U1, . . . , Un were measured, then
the likelihood function would be
n∏
i=1
P (Yi|Xi, C i, Ui)P (Xi, C i, Ui) =
=
n∏
i=1
[
exp{Yi(β0 + βXYXi + βCY T C i + βUY Ui)}
1 + exp{β0 + βXYXi + βCY T C i + βUY Ui}
×
exp{γXXi + γC T C i + γUUi + γXUXiUi + γCY T C iUi + γCX T C iXi + γC T (C i ⊕ C i)}
Q(γX , γC , γU , γXU , γCU , γCX , γC⊕C )
]
.
Because U is unmeasured, the likelihood for the observed data is obtained by integrating over
the binary U . We obtain
L(β0, βXY , βCY , βUY , γX , γC , γU , γXU , γCU , γCX , γC⊕C ) (8)
=
n∏
i=1
[
P (Yi|Xi, C i, U = 0)P (Xi, C i, U = 0) +
P (Yi|Xi, C i, U = 1)P (Xi, C i, U = 1)
]
=
n∏
i=1
[
exp{Yi(β0 + βXYXi + βCY T C i)}
1 + exp{β0 + βXYXi + βCY T C i}
×
exp{γXXi + γC T C i + γCX T C iXi + γC⊕C T (C i ⊕ C i)}
Q(γX , γC , γU , γXU , γCU , γCX , γC⊕C )
+
exp{Yi(β0 + βXYXi + βCY T C i + βUY )}
1 + exp{β0 + βXYXi + βCY T C i + βUY }
×
exp{(γX + γXU )Xi + (γC + γCU )T C i + γCX T C iXi + γC⊕C T (C i ⊕ C i)}
Q(γX , γC , γU , γXU , γCU , γCX , γC⊕C )
]
.
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The posterior distribution is
P (β0, βXY , βCY , βUY , γX , γC , γU , γXU , γCU , γCX , γC⊕C , σ2β , µγ , σ
2
γ , µ0, σ
2
0 |data)
∝ L(β0, βXY , βCY , βUY , γX , γC , γU , γXU , γCU , γCX , γC⊕C )×
P (β0)P (βXY , βCY , βUY |σ2β)P (γXU , γCU , γCX , γC⊕C |µγ , σ2γ)P (γX , γC , γU |µ0, σ20)× (9)
P (σ2β)P (µγ |σ2γ)P (σ2γ)P (µ0|σ20)P (σ20) (10)
where lines (9) and (10) refer to the prior distributions for model parameters.
We sample from the posterior distribution using MCMC and the Metropolis Hastings algo-
rithm [20]. We update sequentially from the conditional densities
[β0, βXY , βCY , βUY |.] [γx, γC , γU |.] [γXU , γCU , γCX , γC⊕C |.]
[σ2β|.] [µγ, σ2γ|.] [µ0, σ20|.],
where “[ |.]” means conditional on the data and remaining model parameters. We update
(β0, βXY , βCY , βUY ), (γx, γC , γU) and (γXU , γCU , γCX , γC⊕C ) using a multivariate random
walk with proposal distributions that are multivariate t-distributed with small degrees of free-
dom and with scale matrix equal to the identity matrix multiplied by a tuning parameter that
is set by trial MCMC runs. Updating σ2β, (µγ, σ
2
γ) and (µ0, σ
2
0) is straightforward in principle
because they are conditionally conjugate and we can sample from the conditional distributions
directly. See Section 3.1 for further discussion of computation and alternatives.
3. Analysis Results for the Beta Blocker Data
3.1 Full Bayesian Analysis
We fit the model in equations (3) and (4) to the beta blocker data and estimate the association
between X and Y while adjusting for C and exploring sensitivity to the unmeasured confounder
U . In the beta blocker data, we are concerned about confounding from unmeasured indications
of disease. The variable U is a binary measure of the severity of heart disease, such as ejection
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fraction or class of heart failure. For this reason, we fix C to include only the q = 9 disease
indicator variables listed in Table 1 because they are informative about patient illnesses. The
remaining p− q = 21− 9 = 12 covariates are not measures of disease (e.g. age and gender) and
they are included via a separate linear terms in the regression model for the outcome. In other
words, we substitute equation (3) with
logit[Pr(Y = 1|X, C , C˜ , U)] = β0 + βXYX + βCY T C + βC˜Y T C˜ + βUYU, (11)
where “. . .+ βC˜Y
T C˜ + . . .′′ refers to the 12 non-disease covariates, denoted C˜ , and we assign
a prior to βC˜Y that is independent normal with mean zero and variance 10
3. Furthermore, we
keep the model for P (X, C , U) exactly as written in equation (4) and exclude a model for the
distribution of covariates C˜ .
A computational challenge with our method is that sampling from the full set of param-
eters can be difficult because of nonidentifiability. As discussed in [2,3,19], the model for
unmeasured confounding is not identifiable. This means is that different points in the pa-
rameter space give identical likelihood functions for the data. The data only minimally influ-
ence the posterior distribution for the bias parameters βUY , γU , γXU , and γCU , which model
unmeasured confounding. Assigning informative prior distributions can improve computa-
tion, but there is still be very slow MCMC mixing, particularly if the sample size of the
dataset is large. A further computational challenge is that the hierarchical prior distributions
in equations (5), (6) and (7) have heavy tails. If we marginalize over the hyperparameters
(σ2β, µγ, σ
2
γ, µ0, σ
2
0), then equation (9) assigns a t-distribution prior to each of the parameters in
the sets (βXY , βCY , βUY ),(γXU , γCU , γCX , γC⊕C ), and (γX , γC , γU) [20]. Using prior distri-
butions with heavy tails is problematic when fitting nonidentifiable models because the MCMC
sampler may drift towards infinity.
One pragmatic solution is to speed MCMC convergence is by estimating the hyperparameters
(σ2β, µµ, σ
2
γ, µ0, σ
2
0) beforehand, and then plugging estimates into the priors in equation (9). This
treats the hyperparameters as fixed and known during MCMC. It replaces t-distributions with
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heavy tailed normals improving convergence. Furthermore, it reduces the dimension of the
parameter space during MCMC, so that fewer parameters need to be updated at each iteration.
However, a disadvantage of this approach is that it ignores uncertainty in the hyperparameters.
This may give interval estimates for model parameters that are too narrow.
To illustrate, we calculate point estimates for the hyperparameters using Table 3. The
quantity σβ is the standard deviation of βXY , βCY , βUY . We estimate this quantity as the
sample standard deviation of the log odds ratios in Section A of Table 3, which is equal to
σˆβ = 0.57. To estimate the hyperparameters µγ and σ
2
γ, we compute the sample mean µˆγ = 0.71
and sample standard deviation σˆγ = 0.93 of the log odds ratios in Section B of Table 3 (See also
Figure 1). To estimate µ0 and σ0 we use Section C of Table 3. First, we compute the logits of
prevalences of {X = 1}, {C1 = 1}, {C2 = 1}, . . . , {Cq = 1}. So for example, the prevalence of
COPD is 310/6969 = 0.044, and the logit of the prevalence is log (0.044/(1− 0.044)) = −3.06.
Similarly, the logit of the prevalence of cancer (CAN) is −3.96. We then compute the sample
mean µˆ0 = −3.86 and the sample standard deviation σˆ0 = 1.22 of the logits.
The point estimates (σˆ2β, µˆγ, σˆ
2
γ, µˆ0, σˆ
2
0) are substituted into the priors in equation (9) so that
updating of the hyperparameters is not required during MCMC. We run a single MCMC chain of
length 1000000 after 100000 burn-in iterations. Sampler convergence is assessed using separate
simulation runs with overdispersed starting values and the diagnostics tools included in the R
package CODA [22].
The results are given in the second column of Table 1. The column has the heading
“U 6⊥⊥ C |X” in order to indicate that the components of γCU are modelled as exchangeable
with the components of (γXC , γCX , γC⊕C ) in equation (6), and therefore, that the analysis
does not assume that γCU = 0 . The log odds ratio for the beta blocker effect parameter
βXY is -0.31 with 95% credible interval (-0.64, 0.07). This point estimate is nearly identical to
that obtain from the NAIVE analysis. But the interval estimate is wider because the Bayesian
analysis acknowledges uncertainty from unmeasured confounding. The prior distributions in
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equation (5) assumes that the bias parameter βUY has a prior mean zero and standard deviation
σˆβ = 0.57. In other words, the sensitivity analysis assumes that U is associated with Y , given
(X,C), and this association may either increase or decrease the probability of Y . Because the
prior is symmetric at zero, this means that the estimated value for βXY is similar to that of the
Naive analysis, but the interval estimate is wider. Similar results are reported by McCandless
et al. [2,3].
3.2 Assessing Prior Sensitivity for γCU
Our modelling framework gives the opportunity to study the role of γCU in sensitivity
analysis for unmeasured confounding. One issue is assessing the impact of the usual assumption
that γCU = 0. Recall from Section 1.2 that most sensitivity analysis techniques assume that
measured and unmeasured confounders are uncorrelated (i.e. U ⊥⊥ C |X) in order to reduce
the burden of prior elicitation.
To study the effect of this assumption, we redo the Bayesian analysis in exactly the same
way as Section 3.1, but change the prior in equation (6) to be
γCU = 0 (12)
γXU , γCX , γC⊕C
IID∼ N{µˆγ, σˆ2γ},
where µˆγ = 0.71 and σˆγ = 0.93. This sets each component γCU equal to zero and guarantees
that U ⊥⊥ C |X. However, it permits the other three bias parameters βUY , γUX and γU to be
non-zero. Thus using the prior in equation (12) instead of (6) allows U to be an unmeasured
confounder for the effect of X and Y , despite the fact that U ⊥⊥ C |X.
The results are presented in the third column of Table 1 under the heading “U ⊥⊥ C |X”. As
intuition suggests, assuming that γCU = 0 increases the posterior uncertainty about unmea-
sured confounding in the beta blocker data. The credible interval for the beta blocker effect in
the third column (U ⊥⊥ C |X) is nearly 15% wider than in the middle column where U 6⊥⊥ C |X.
We have 95% interval estimates (-0.66, 0.15) versus (-0.64, 0.07). Both Bayesian analyses ac-
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knowledge uncertainty from unmeasured confounding, but only the exchangeable analysis allows
the possibility that U and C are correlated. The magnitude of this correlation is driven by the
hyperparameter estimates µˆγ = 0.71 and σˆγ = 0.93, which in turn are estimated from the joint
distribution of X and C .
To illustrate the prior sensitivity more clearly, we repeat the analysis while toying with fixed
values for γCU . Figure 2 illustrates what happens to the posterior distribution of βXY when
we set γCU equal to 0 versus 1 . . . versus 5. The quantities 0 , 1 , . . . , 5 denote vectors of
length p + 1. For example, 0 = (0, 0, . . . , 0) and 1 = (1, 1, . . . , 1). When γCU = 5 then this
means that the odds ratios for the conditional association between U and each of component
C is equal to exp(5) = 148, which corresponds to roughly perfect correlation between C and
U . In Figure 2, the grey shaded region indicates the width and positioning of the Naive interval
estimate for βXY , which is (-0.48, -0.16). Additionally, each of the interval estimates in the
figure is an interval estimate for βXY that is calculated by doing a Bayesian sensitivity analysis
with γCU locked at either 0,1, . . . ,5.
The key observation is that when γCU is large, the interval estimates collapse towards the
shaded region and we obtain inferences that are essentially identical to assuming that there is
no unmeasured confounding. If U and C are highly correlated, then this means that regression
adjustment for C eliminates confounding from U , despite the fact that U is unmeasured. This
occurs even though the prior distribution on the bias parameters βUY , γUX and γU are non-zero.
In other words, if an unmeasured confounder U is associated with the treatment and outcome,
then it may nonetheless induce essentially no bias upon adjustment for C , provided that C is
sufficiently correlated with U .
In Figure 2, the interval estimates are shifted slightly towards zero compared to the shaded
region. The reason is because of the informative prior on βXY in equation (5). The prior has
mean zero and variance σˆβ = 0.57, which tends to shrink point estimates for βXY towards the
zero. In contrast, the Naive interval estimate in Table 1 is computed by maximum likelihood,
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which effectively presumes a flat prior on βXY .
4. Discussion
Recent years have witnessed new innovation in Bayesian techniques to adjust for unmeasured
confounding in observational studies. A challenge is that the user is often required to elicit prior
distributions for high dimensional parameters that model competing bias scenarios. This can
render the methods unwieldy. In this paper, we propose a novel methodology for settings where
the confounding effects of measured and unmeasured variables can be viewed as exchangeable
within a Bayesian framework. Exchangeability captures the intuitive idea put forth by Joffe [18]
that confounding from measured variables may be informative about unmeasured variables. Our
method reduces the burden of prior elicitation in sensitivity analysis because it assigns priors to
bias parameters without requiring that the analyst encode assumptions about each parameter
individually.
Exchangeability is appealing in pharmacoepidemiology where confounding often results from
a collection of homogeneous disease-related variables that influence prescribing. See Schneeweiss
[1] and Joffe [18] for discussion of unmeasured confounding in pharmacoepidemiology. One
example is observational studies of the effects of antidepressant drugs on adverse outcomes
including infertility [23] and suicide [24]. An important confounder is depression, which is
associated with antidepressant use. Because depression is difficult to measure and adjust for, it
can produce a bias that is difficult to predict. However, one could argue that in typical scenarios
the confounding induced by depression is indistinguishable, a priori, from the confounding of
other disease-related variables that influence antidepressant use, such as cancer, alcohol abuse,
sleep disorders, injury or other mental illness [24].
The assumption of exchangeability of measured and unmeasured confounders is a strong
one. However it is only contingent on making judgments about the labelling of the indices of
the parameters in the prior distribution (See Section 2.2). An exchangeable prior is plausible
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for a set of parameters if, based on available information, we are unable to distinguish one
parameter for another. For the beta blocker data, the unmeasured confounder U is either
ejection fraction or class of heart failure, both of which are measures of the severity of heart
disease. The confounding from U is poorly understood, and there is only limited information
available in the literature to characterize the dependence between U and C (see for example
[17]). A priori, we have no reason to believe that the confounding from U is any different from
the confounding from the q = 9 disease indicator variables.
An advantage of our method is that it does not make the usual sensitivity analysis assump-
tion that U ⊥⊥ C |X (see [1-3,6,8,9,12-14] for examples and discussion). We use a loglinear
model for the joint distribution of (X, C , U), and assign a hierarchical prior distribution to
the bias parameter γCU , which models the dependence between the measured and unmeasured
confounders, conditional on X. In Section 3, we show that when γCU is non-zero then this
reduces the uncertainty from unmeasured confounding. In the beta blocker data, the convention
of forcing γCU = 0 for convenience gives results that are too pessimistic.
An important limitation of our method is that we substitute point estimates for the hyper-
parameters into the prior distribution in order to improve MCMC computation (See Section
3.1). In our experience, this substantially reduces computational time. However, it also ignores
uncertainty in the hyperparameter estimates and may give interval estimates that are too nar-
row. This will be important if the number of measured confounders p is small. In this setting,
it is difficult to characterize the patters of confounding in the dataset, and the uncertainty in
hyperparameter estimates may be large. Nonetheless, pharmacoepidemiological studies often
utilize healthcare administrative data with large sample sizes and rich covariate information on
study participants.
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